Table 2.
Characteristics of patients included in the second-line cohort (n = 719)
| Characteristic at second-line initiation | Total (n = 719) |
Switched to third-line (n = 36) |
Patients remaining on second-line (n = 683) |
|
|---|---|---|---|---|
| Gender | N, % | |||
| Male | 239/719 (33.2%) | 12/36 (33.3%) | 227/683 (33.2%) | |
| Female | 480/719 (66.8%) | 24/36 (66.7%) | 456/683 (66.8%) | |
| Current age, years | Median, IQR | 39.4 (33.3-46.3) | 40.0 (35.2-46.8) | 39.3 (33.3–46.3) |
| < 30 | N, % | 92/719 (12.8%) | 4/36 (11.1%) | 88/683 (12.9%) |
| 30–45 | 417/719 (58.0%) | 20/36 (55.6%) | 397/683 (58.1%) | |
| ≥ 45 | 210/719 (29.2%) | 12/36 (33.3%) | 198/683 (29.0%) | |
| Current CD4 count, cells/mm3 | Median, IQR | 415.0 (253.0-583.0) | 298.5 (183.0-397.0) | 420.5 (255.0–592.0) |
| < 100 | N, % | 49/600 (8.2%) | 4/26 (15.4%) | 45/574 (7.8%) |
| 100–200 | 61/600 (10.2%) | 3/26 (11.5%) | 58/574 (10.1%) | |
| 200–350 | 131/600 (21.8%) | 8/26 (30.8%) | 123/574 (21.4%) | |
| ≥ 350 | 359/600 (59.8%) | 11/26 (42.3%) | 348/574 (60.6%) | |
| Missing | 119 | 10 | 109 | |
| Current second-line regimen | N, % | |||
| AZT + ddI + LPVr | 7/719 (1.0%) | 1/36 (2.8%) | 6/683 (0.9%) | |
| TDF + 3TC/FTC + LPVr | 247/719 (34.4%) | 10/36 (27.8%) | 237/683 (34.7%) | |
| AZT + 3TC + LPVr | 259/719 (36.0%) | 16/36 (44.4%) | 243/683 (35.6%) | |
| Other | 206/719 (28.7%) | 9/36 (25.0%) | 197/683 (28.8%) | |
| Current viral load, copies/mL | Median, IQR | 249.5 (51.0-2791.5) | 6510.0 (1505.0-32,718.0) | 235.0 (49.0–1932.0) |
| < 1000 | N, % | 453/660 (68.6%) | 8/33 (24.2%) | 445/627 (71.0%) |
| 1000–50,000 | 140/660 (21.2%) | 19/33 (57.6%) | 121/627 (19.3%) | |
| ≥ 50,000 | 67/660 (10.2%) | 6/33 (18.2%) | 61/627 (9.7%) | |
| Missing | 59 | 3 | 56 | |
| Year of second-line initiation | N, % | |||
| 2004–2010 | 313/719 (43.5%) | 22/36 (61.1%) | 291/683 (42.6%) | |
| 2010–2012 | 406/729 (56.5%) | 14/36 (38.9%) | 392/683 (57.4%) | |
| Initiating second-line regimen | N, % | |||
| AZT + ddI + LPVr | 119/719 (16.6%) | 10/36 (27.8%) | 109/683 (16.0%) | |
| TDF + 3TC/FTC + LPVr | 196/719 (27.3%) | 6/36 (16.7%) | 190/683 (27.8%) | |
| AZT + 3TC + LPVr | 163/719 (22.7%) | 6/36 (16.7%) | 157/683 (23.0%) | |
| Other | 241/719 (33.5%) | 14/36 (38.9%) | 227/683 (33.2%) | |
| Never suppressed on second-line ART prior to August 2012 | N, % | 90/595 (15.1%) | 9/33 (27.3%) | 81/562 (14.4%) |
| Missing | 124 | 3 | 121 | |
| Viral load blips on second-line prior to August 2012 | N, % | |||
| 0 | 317/488 (65.0%) | 16/30 (53.3%) | 301/458 (65.7%) | |
| ≥ 1 | 171/488 (35.0%) | 14/30 (46.7%) | 157/458 (34.3%) | |
| Missing | 231 | 6 | 225 | |
| Time to first viral load on second-line ART, days | Median, IQR | 175.0 (125.0–252.0) | 169.0 (118.0–280.0) | 175.0 (126.0–244.0) |
| Total person time calculated from 01 August 2012, months | Median, IQR | 53.5 (44.7–53.5) | 12.4 (8.0–25.3) | 53.5 (51.9–53.5) |
ABC abacavir; 3TC lamivudine; FTC emtricitabine; LPVr lopinavir ritonavir; TDF tenofovir; AZT zidovudine; ddI didanosine; d4T stavudine, IQR interquartile range